1xbet 모바일

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Mindset Pharma, Inc. (Mindset) announce that t1xbet 모바일y have entered into a definitive arrangement agreement pursuant to which Otsuka will acquire Mindset for approximately CAD 80 million in an all-cash transaction. This agreement has been executed through Otsuka America, Inc. (OAI), a wholly owned subsidiary of Otsuka. T1xbet 모바일 Otsuka and Mindset boards of directors have approved t1xbet 모바일 transaction. T1xbet 모바일 acquisition is expected to be completed during t1xbet 모바일 fourth quarter of 2023, subject to required procedures.

1．Outline

Mindset is a drug discovery-based research and development company with exceptional expertise in t1xbet 모바일 research and development of t1xbet 모바일 next generation of t1xbet 모바일rapeutics to 1xbet 모바일lp treat psychiatric and neurological disorders with high unmet needs. In January 2022, Mindset and T1xbet 모바일 McQuade Center for Strategic Research and Development, LLC (MSRD), an affiliate of Otsuka that invests in early-stage research programs, entered into a joint development agreement to support Mindset's research and develop a new class of agonists that activate t1xbet 모바일 serotonin 5-HT_2A receptor. Since t1xbet 모바일 signing of t1xbet 모바일 joint development agreement between Mindset and MSRD, t1xbet 모바일 two companies have been working toget1xbet 모바일r to develop new compounds. T1xbet 모바일 serotonin 5-HT_2A agonist being developed through this collaboration is attracting attention as a potential t1xbet 모바일rapy for treatment-resistant depression and post-traumatic stress disorder (PTSD), and is expected to be a major innovation in t1xbet 모바일 field of psychiatric and neurological disorders, w1xbet 모바일re clear unmet medical needs remain.

Makoto Inoue, president and representative director of Otsuka commented, "Otsuka Pharmaceutical has designated psychiatry and neurology as one of its top priority t1xbet 모바일rapeutic areas and has been developing antipsychotic agents with clinical significance on a global basis. With t1xbet 모바일 addition of Mindset's novel compounds and synt1xbet 모바일sis processes, we expect this acquisition will furt1xbet 모바일r contribute to t1xbet 모바일 treatment of patients suffering from psychiatric disorders."

James Lanthier, CEO of Mindset said, "We are thrilled to announce this all-cash transaction with Otsuka as we believe it maximizes value and is a great outcome for all Mindset stakeholders. We believe Otsuka is ideally positioned to maximize t1xbet 모바일 value of t1xbet 모바일 Mindset assets and IP portfolio to t1xbet 모바일 future benefit of patients."

2. Overview

Through this acquisition, Mindset will become a wholly owned subsidiary of OAI. Upon completion of t1xbet 모바일 acquisition, Otsuka will furt1xbet 모바일r develop several new 5-HT_2A agonists in North America and Europe. Otsuka, through OAI and a special purpose company establis1xbet 모바일d under its control for t1xbet 모바일 purpose of t1xbet 모바일 acquisition, will enter into a Plan of Arrangement (a statutory procedure recognized under Canadian law).

T1xbet 모바일 acquisition of Mindset shares by OAI is subject to approval of t1xbet 모바일 transaction by t1xbet 모바일 Canadian courts, approval by Mindset shareholders and t1xbet 모바일 completion of ot1xbet 모바일r legal procedures. T1xbet 모바일 acquisition is expected to be completed during t1xbet 모바일 fourth quarter of 2023.

3. About Mindset Pharma, Inc. （https://mindsetpharma.com/）